Biocon

Biosimilars / insulin

BIOCON · NSE · India

Public Market Listing

BIOCONNSE

NSE primary exchange listing

Live quotes, historical charts, and market capitalization for Biocon are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
12Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma, Advanced Metastatic Colorectal Cancer
Phase 1
CD6Monoclonal antibody
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-FY$1.9B$111M$259M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.8B$101M$378M—report ↗
2024-FY$1.8B$140M$148M—report ↗
2023-FY$1.4B$148M$161M—report ↗
2022-FY$1.1B$95M$87M—report ↗